Optiscan Brings InVue Real-Time Surgical Imaging to FDA Review

Optiscan Imaging Ltd (ASX:OIL) has moved its InVue precision surgery device into formal US regulatory review, lodging a 510(k) application with the Food and Drug Administration. The filing is a significant development milestone for a platform designed to show surgeons microscopic, cellular-level information in real time while a patient remains in the operating theatre.

It is not, however, a clearance. The FDA will assess the technical, performance and clinical evidence in the application and may request clarification or additional information before deciding whether InVue meets the requirements for clearance.

InVue Targets Real-Time Surgical Decision-Making

Optiscan says InVue is initially aimed at surgical oncology, where clinicians must determine during an operation whether suspicious or residual tumour remains. The device is intended to provide information at the surgical site rather than relying solely on the conventional process of removing tissue and sending it away for laboratory preparation.

The company identifies potential applications across breast, head and neck, colorectal, genitourinary, skin and other solid-tumour procedures. Those claims describe a broad platform opportunity, not an established clinical or commercial outcome. Optiscan cites an estimated US$4.8 billion annual cancer treatment facilities market and a projected US$1.55 billion US intraoperative imaging market by 2030, while acknowledging that InVue must still clear the regulatory and adoption hurdles before it can address those markets.

FDA Submission Follows InForm Milestone

The InVue application comes shortly after Optiscan lodged a separate 510(k) application for InForm, its digital pathology device. Taken together, the submissions put both products into the FDA review process and give the company two regulatory programs advancing towards potential US market entry, although neither application has yet resulted in clearance.

For InVue, the submission follows work covering engineering, external testing, clinical validation, risk management and regulatory preparation. Optiscan says clinical studies will continue beyond the filing, generating further data across surgical workflows while the company engages surgeons and clinical partners, develops reference sites, prepares manufacturing scale-up and discusses potential commercial partnerships.

Review Outcome Remains the Next Critical Test

CEO and managing director Dr Camile Farah described the filing as a key deliverable in Optiscan’s development strategy and said the technology could give surgeons more information at the point of decision-making. Those comments are forward-looking: the company’s own announcement says FDA clearance would be the gateway to commercialisation in the US, rather than presenting market entry as secured.

The immediate test is therefore regulatory rather than revenue-related. The timing of the FDA process, any requests for additional evidence, the indications included in a potential clearance and the strength of subsequent clinical and commercial uptake will determine how much of InVue’s stated opportunity can translate into an operating business.